Skip to content

Australian study of the effects of strict potassium restriction on nerve function in patients with chronic kidney disease

Australian study of the effects of strict potassium restriction on neuropathy in chronic kidney disease

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12610000538044
Acronym
AUSSPRINT
Enrollment
47
Registered
2010-07-05
Start date
2010-08-26
Completion date
2012-11-23
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

People with kidney failure often develop a condition called ‘uraemic neuropathy’, where the function of the nerves in the hands and feet is impaired. These changes cause weakness, numbness and tingling. Our studies have shown that high levels of potassium in the bloodstream may cause uraemic neuropathy. The purpose of this study is to investigate whether reducing the amount of potassium in a patient’s diet may help prevent neuropathy.

Interventions

Strict dietary potassium (K+) restriction with Dietitian support - including an initial consultation, 2 week follow-up consultation with fortnightly phone calls for the first 3 months after which the patient will receive a phone call one month and a face to face consultation the next for the remaining months of the total 24 month trial. If serum K+ levels exceed the target of 3.5-4.5mmol/L for more than 2 months dietary advice will be supplemented by an oral solution of resonium (15-30mg per ni

Strict dietary potassium (K+) restriction with Dietitian support - including an initial consultation, 2 week follow-up consultation with fortnightly phone calls for the first 3 months after which the patient will receive a phone call one month and a face to face consultation the next for the remaining months of the total 24 month trial. If serum K+ levels exceed the target of 3.5-4.5mmol/L for more than 2 months dietary advice will be supplemented by an oral solution of resonium (15-30mg per night as prescribed by the treating physician based on the clinical variables) until K+ falls back within normal range.

Sponsors

Dr Arun Krishnan
Lead SponsorIndividual

Study design

Allocation
Randomised controlled trial
Intervention model
Factorial
Primary purpose
Prevention
Masking
Blinded (masking used)

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

History of Chronic Kidney Disease (stage 3 or 4), as defined by the estimated glomerular filtration rate. Monthly attendance for clinical care at Kidney Care Centre, Prince of Wales Hospital. Able to provide informed consent

Exclusion criteria

Current or past history of dialysis therapy or previous renal transplantation. Cognitively impaired Unable to speak and/or understand English Pregnant

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026